Q4 25 EPS
$0.24
BEAT +10.75%
Est. $0.22
Q4 25 Revenue
$157.9M
BEAT +1.91%
Est. $154.9M
vs S&P Since Q4 25
-9.7%
TRAILING MARKET
BVS -0.6% vs S&P +9.1%
Full Year 2025 Results
FY 25 EPS
$0.68
FY 25 Revenue
$568.1M
Market Reaction
Did BVS Beat Earnings? Q4 2025 Results
Bioventus capped fiscal 2025 with a notably strong fourth quarter, posting adjusted EPS of $0.24 against a consensus estimate of $0.22 while reporting revenue of $157.90 million, up 2.8% year-over-year on a reported basis and 10.0% organically. The p… Read more Bioventus capped fiscal 2025 with a notably strong fourth quarter, posting adjusted EPS of $0.24 against a consensus estimate of $0.22 while reporting revenue of $157.90 million, up 2.8% year-over-year on a reported basis and 10.0% organically. The profitability turnaround was the headline story: the company swung to GAAP net income attributable to Bioventus of $14.76 million from a net loss of $388,000 in Q4 2024, powered by double-digit organic growth in both Pain Treatments and Surgical Solutions, gross margin expansion to a non-GAAP 75.5%, and disciplined cost controls that widened non-GAAP operating margin to 21.1% from 16.9%. Pain Treatments was the standout, generating $79.66 million in revenue, up 15.1%, on robust demand for hyaluronic acid viscosupplementation therapies. Full-year operating cash flow rose 92% to $74.67 million, with the company also reducing debt by $29.00 million in the quarter. Looking ahead, management guided 2026 net sales of $600 million to $610 million and adjusted EPS of $0.73 to $0.77, reflecting continued above-market growth expectations.
Key Takeaways
- • Strong demand for differentiated hyaluronic acid therapies for knee osteoarthritis drove Pain Treatments growth
- • Higher U.S. demand for Bone Graft Substitutes supported Surgical Solutions
- • Improved commercial effectiveness and sales force execution with EXOGEN Bone Stimulation System
- • Gross margin expansion with non-GAAP gross margin improving to 75.5% from 73.7%
- • Disciplined spending and cost management
- • 10.0% organic revenue growth across the portfolio
BVS YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
BVS Revenue by Segment
With YoY comparisons, source: SEC Filings
BVS Revenue by Geography
With YoY comparisons, source: SEC Filings
“Our team delivered strong fourth quarter performance, concluding an important year in which we strengthened our portfolio, drove above-market growth, improved margins, and strengthened our balance sheet. These results reflect continued demand for our market-leading therapies, and disciplined execution across our commercial and operational initiatives. We are entering 2026 from a position of strength and plan to invest to further accelerate our growth while expanding profitability and generating meaningful cash flow. We believe this is a powerful combination that positions Bioventus to deliver increased shareholder value.”
— Rob Claypoole, Q4 2025 Earnings Press Release
BVS Earnings Trends
BVS vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BVS EPS Trend
Earnings per share: estimate vs actual
BVS Revenue Trend
Quarterly revenue: estimate vs actual
BVS Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $0.07 | $0.15 | +120.59% | $132.1M | +1.69% |
| Q4 25 BEAT FY | $0.22 | $0.24 | +10.75% | $157.9M | +1.91% |
| FY Full Year | — | $0.68 | — | $568.1M | — |
| Q3 25 BEAT | $0.12 | $0.15 | +30.43% | $138.7M | +0.34% |
| Q2 25 BEAT | $0.20 | $0.21 | +6.76% | $147.7M | +1.23% |
| Q1 25 BEAT | $0.02 | $0.08 | +250.88% | $123.9M | +0.95% |